Type V Collagen Treatment Increases Caspase-9 Expression in Murine Lung Cancer
ER Parra, CM Vargas, LC Bielecki, JMFP Ribeiro, FA Balsalobre, WR Teodoro, W de Souza, VL Capelozzi. Faculdade de Medicina da Universidade de So Paulo, So Paulo, Brazil
Background: Type V collagen (COL V) is a component of the extracellular matrix (ECM) located in pulmonary interstitium and capillary basement membranes. Recently, this collagen has shown efficient as tumoral and endothelial apoptotic-promoter emerging promise as inductor of death response via caspase 9. In this study, we sought to examine the interface of COL V and endothelial apoptosis in experimental lung cancer.
Design: Four groups of mice Balb/c males were studied: a) control (n=5), b) animals that received two doses of 3g/kg intraperitoneal of Uretane (n=10), c) animals that received two doses of 3g/kg intraperitoneal of Uretane and treatment with COL V intranasal administration of 20 mug for 2 months after 2 months of uretane administration (n=10), and d) animals that received only intranasal COL V (n=5). The mice were sacrificed after 6 months. Lung histological sections underwent hematoxylin-eosin, immunofluoresce for COL V and immunohistochemistry for Caspase 9 methods for morphometric analysis.
Results: Collagen V (7.19 2.81) and caspase 9 (5.99 2.55) densities in tumoral area were lower when compared with normal surrounding parenchyma (12.31 0.79) and control (9.67 3.20) groups. The intranasal COL V administration in animals with lung cancer increased the caspase 9 expression rate by tumoral endothelial cells (16.06 4.36) when compared with other groups (p<0.01).
Conclusions: Collagen V intranasal treatment induces increased endothelial immune expression of caspase 9 in tumoral areas of experimental lung cancer, thus leading to decreased angiogenesis by high endothelial death rate. Further studies will be required in randomized and prospective trials to validate the therapeutic efficacy of type V collagen. Financial supported: FAPESP.
Tuesday, March 10, 2009 1:00 PM
Poster Session IV # 248, Tuesday Afternoon